Main difference: time required to reach maintenance dose.

Slides:



Advertisements
Similar presentations
Managing CF patients with antibiotic hypersensitivity
Advertisements

The Diabetic Retinopathy Clinical Research Network
Food Allergy Highlights of the past 3 years Adam Fox Paediatric Study Day Cheltenham June 2004 Dr Adam Fox.
Why immunotherapy fails ? Stephen Durham Imperial College and Royal Brompton Hospital, London UK.
Allergen Immunotherapy: From Shots to Tablets Susan Waserman MSc MDCM FRCPC Professor of Medicine Division of Clinical Allergy and Immunology Life and.
C A SHINKWIN BON SECOURS GP STUDY DAY 28 JANUARY, 2012.
Treat Allergies Not Just The Symptoms!™ ”WITHOUT NEEDLES”
Insect Sting Allergy and Venom Immunotherapy David B.K. Golden, M.D. Johns Hopkins University, Baltimore.
Allergy, Anaphylaxis & Immune Reactions Christine Kennedy & Katharine Smart.
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.
Allergy, Asthma and Immunotherapy Give Your Patients Back Their Lives S545v2.
Dr Narayana pradeep Consultant Pulmonologist Carewell hospital KasaragodKERALA.
Badrul A. Chowdhury, MD, PhD
Methylphenidate Transdermal System (MTS): Safety Issues Robert Levin, M.D. Medical Officer Division of Psychiatry Products Center for Drug Evaluation and.
Inhaled corticosteroids in preschool asthmatic children
Agency for Healthcare Research and Quality (AHRQ)
Understand the Difference between Local and Systemic Reactions Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee.
Use of Multiple Allergen Mixes in Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health University of Colorado Denver School.
Food Allergy By Dr Rowan Brown. Problem Common - ( % of population) Attitude - Medical vs Common Opinion Service Provision - access to specialist.
Bepotastine Besilate Ophthalmic Solution 1.5% and Degree of Reduced Ocular Itching in a Conjunctival Allergen Challenge Test JI Williams 1, G Torkildsen.
Authors: Petersen KD §1, Kronborg C 2, Beck SJ 3, Larsen JN 4, Dahl R 5, Gyrd-Hansen D 2, 6 §1 Corresponding: Karin Dam Petersen, Danish Centre for Healthcare.
WAO Anaphylaxis Guidelines-WAO Anaphylaxis Special Committee Epidemiology 7 December 2011 Workshop 25.
1 Anaphylaxis training course Providing up-to-date information about managing severe allergies in schools.
Simplification of Bevacizumab Administration: Do we need 90, 60, or even 30 minute infusion times? LB Saltz, K-Y Chung, D Reidy, J Timoney, V Park, E.
Allergic Rhinitis Richard Douglas. Prevalence Most common disease 20% adult population.
1 Environmental Exposure Units for Phase 3 Studies Ronald L. Rabin, MD Chief, Laboratory of Immunobiochemistry Center for Biologics Evaluation and Research.
Allergy Test: Seasonal Allergens and Performance in School Dave E. Marcotte Journal of Health Economics, 2014 Presented by: Josh Vojtush.
T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.
Allergy Symptom Response Following Conversion from Injection Immunotherapy to Sublingual Immunotherapy CDR Timothy Clenney, MD, MPH Naval Medical Center.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Anti-IgE in Asthma and Other Allergic Diseases Harold S. Nelson. MD Professor of Medicine National Jewish Health And University of Colorado School of Medicine.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
SLIT: dealing with trouble, doing it right. Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy.
Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.
Rush and Cluster Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health University of Colorado Health Science Center Denver, Colorado.
EVALUATION OF THREE ALLERGEN SPECIFIC IMMUNOTHERAPY METHODS Standard Injection RUSH Injection Sublingual Abstract# 54 Richard Herrscher M.D. FACAAI Clinical.
A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.
Therapeutic Drug Monitoring (TDM) Sticker Project A New Method for Documenting Times of Medication Doses and Drug Levels.
Asthma Management and the Allergist: Better Outcomes at Lower Cost.
Which Patients for Subcutaneous Immunotherapy? Harold S. Nelson. MD Professor of Medicine National Jewish Heath University of Colorado Denver School of.
SLIT and Atopic Dermatitis George F. Kroker, MD ©2008 Allergychoices, Inc. All Rights Reserved.
Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.
Cost Effectiveness of Allergy Care. Asthma Patients Cared for by Allergists Have: Fewer emergency care visits Fewer hospitalizations Reduced length of.
1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.
COSTS STUDY OF SEVERE PNEUMONIA IN AN EQUIVALENCE TRIAL OF ORAL AMOXICILLIN VERSUS INJECTABLE PENICILLIN IN CHILDREN AGED 3 TO 59 MONTHS Patel AB, APPIS.
SUBLINGUAL IMMUNOTHERAPY Giovanni Passalacqua Allergy & Respiratory Diseases Dept.Internal Medicine- University of Genoa ITALY.
Monotherapy for the polysensitized patient Noel Rodriguez-Perez, MD Professor of pediatrics State University of Tamaulipas, Mexico.
Advances in Pediatric Asthma Care Keyvan Rafei, MD, MBA Division Head, Pediatric Emergency Medicine Chairman, Pediatric Asthma Program.
Long-term Mortality Among Adults With Asthma A 25-Year Follow-up of 1,075 Outpatients With Asthma Zarqa Ali, MD; Christina Glattre Dirks, MD, PhD; and.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Sublingual Allergy Treatment. Sublingual Immunotherapy Immunotherapy is widely used by allergy specialists because it treats the underlying cause of allergic.
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
The PRECIS-2 tool: Matching Intent with Methods David Hahn, MD, MS, WREN Director Department of Family Medicine & Community Health University.
Immunotherapy for Allergic Rhinitis
Sublingual Immunotherapy
Volume 11, Pages (September 2016)
Short course specific immunotherapy for seasonal allergic rhinoconjunctivitis and its impact on quality of life C. Corps1 *, J. Toolan1, K. Ford1, A. Mistry1,
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Practical aspects Of SLIT
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial  Laila Hellkvist, MD,
Allergic rhinobronchitis: The asthma–allergic rhinitis link
Guidelines for Initiation of Therapy
The efficacy and safety of omalizumab in pediatric allergic asthma
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis  Thomas B. Casale, MD, William.
House dust mite sublingual immunotherapy: Results of a US trial
The correlation between allergic rhinitis and sleep disturbance
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

Main difference: time required to reach maintenance dose.

 Cluster immunotherapy  Accelerated build-up schedule  Entails administering several injections at increasing doses (generally 2-3 per visit) sequentially in a single day of treatment on nonconsecutive days  The maintenance dose is generally achieved more rapidly than with a conventional (single injection per visit) build-up schedule (generally within 4 to 8 weeks)

Total injections to maintenance: 18 Total injections to maintenance: 18 Total injections to maintenance: 30 Total injections to maintenance: 30

“Leisurely desensitisation”  Inoculations given weekly merely because our outpatients were in the habit of coming every week.  In view of subsequent quicker methods I have called this older method “leisurely.” April, 1930

“Intensive desensitisation”  Later, I fell into the way of inoculating these patients every day with gradually increasing doses (a 10 to 20 percent increase).  This intensive method proved so successful, and was in some ways so convenient, that I have used it increasingly ever since. “Rush desensitisation”  The injections are given every hour and a half to two hours throughout a 14 hour day. Thus a very satisfactory course can be put through in from two to four days.  The patient must go into hospital, or at any rate be in the charge of a trained nurse, under the constant supervision of a doctor. April, 1930

 Clinical benefit of IT obtained sooner (reach maintenance vial promptly before allergy season)  Increased adherence to schedule? The most common reasons for noncompliance with IT included inconvenience, precluding medical conditions, and adverse systemic reactions (More, Annals 08)  Patients that turn down conventional IT might choose cluster if given the option. Only 5% of patients with allergic asthma and/or AR receive IT.

 Fewer total injections also result in:  Less opportunity for administration errors  Less expensive build-up phase of IT (less allergen and associated supplies needed, fewer insurance copays)

 AIPP: “…slightly increased frequency of systemic reactions”  >1 injection per visit, >1 opportunities to have a reaction at that visit

 Very few studies compare cluster with conventional IT head-to-head  Few studies use the same:  Cluster (or conventional) injection schedule  Allergens  Patient population  Target maintenance dose  Definition of systemic reaction  Some studies premedicate!  Measures of clinical efficacy  Length of study

DB comparative study of cluster and conventional IT schedules with D. pteronyssinus (Tabar, JACI 05) Subjects: pediatric & adult, asthma and/or AR IT ScheduleAdverse rxn rateClinical efficacy Cluster (120) 6 wk (4/3/2/2/2/1 inj per wk) No difference between schedules All systemic rxn mild (grade ≤2); 0.22% of inj Cluster ≥ conv. at 6, 12, 52 wks (asthma sx score, rhinitis score, PEFR variability) Conventional (119) 12 wk (1 inj per wk) Systemic reactions not broken down by phase of IT

Comparative Study of Cluster and Conventional IT Schedules with D. pteronyssinus in the Treatment of Persistent AR (Zhang, Int Arch All Imm 09) Subjects: Adult, ARIT ScheduleAdverse rxn rateClinical efficacy Cluster (48) 6 wk (3/2/2/2/2/1 inj per wk) No difference between schedules All systemic rxn mild (grade ≤2); 1% of cluster inj, 1% of conv inj Cluster ≥ conv. at 6, 14, 52 wks (sx score, rhinitis score, med use score, RQLQ) Conventional (48) 14 wk (1 inj per wk) Systemic reactions during build-up phase: 0.8% of cluster inj vs. 0.74% of conv inj

Safety and Immunogenicity of Cluster IT in Children with Asthma and Mite Allergy (Schubert, Int Arch All Imm 2009) Subjects: Peds, mild-mod asthma with FEV 1 ≥70 IT ScheduleAdverse rxn rate Cluster (22) 6 wk ( 3/3/3/2/1/1 inj per wk) No difference between schedules All systemic rxn mild (cough and dyspnea, grade ≤2); 3.5% of cluster inj vs. 4.6% of conv inj (build-up) Conventional (12) 14 wk (1 inj per wk)  Did not assess clinical efficacy  Maintenance dose of Der p 1 was 5000 TU(?)  Small study excluding severe asthma Community Based Experience with Cluster IT (Harvey, JACI abstract 2/2006) Peds/adult with asthma/AR, (?allergen), 9 wk cluster (n=48) vs. 22 wk conventional (24) Systemic rxn mild (tx with antihistamines); 0.3% of cluster inj vs. 0.2% conventional inj

Conventional IT Systemic Reaction Rates StudyTypeInjectionsSystemic rxn rate Ragusa, Eur Ann All Clin Imm 04 Retrospective single center (Italy, 20 yr period) 435,854.06% of inj (1 st 10 years).01% of inj (2 nd 10 years) Moreno, Clin Exp All 2004 Prospective multicenter (Spain) 17,5260.3% of inj  Basic design of prospective cluster IT studies: enroll patients, put them on cluster protocol, report outcome.  Can compare cluster studies’ reaction rates with published conventional IT studies:

 Clinical efficacy not reported  Maintenance doses a little questionable Safety of Two Cluster Schedules for SCIT in AR or Asthma Patients Sensitized to Inhalant Allergens (Pfaar, Int Arch All Imm 2009) Subjects: Adult, AR and/or asthma IT ScheduleAdverse rxn rate HDM IT (47) Der p 1 & Der f 1 3 wks (3/2/2 inj per wk) All systemic reactions mild; pollen 0.1% of inj, dust mite 0.3% of inj LLR; pollen 3.6% of inj, DM 1.9% of inj Pollen IT (110) 5 grass mix olive + 3 grass mix 3 tree mix 4 wks (3/3/2/2 inj per wk) AllergenMaint doseProbable eff. dose Der p 18 μg μg Phl p 55.6 μg μg Bet v 140 μg μg

Prospective safety study of IT administered in a cluster schedule (Serrano, J Invest Allergol Clin Imm 2004) Subjects: Adult, AR and/or mild-moderate asthma IT ScheduleAdverse rxn rate D. Pteronyssinus IT (38) 6 wk (3/3/2/2/2/2 inj per wk) Systemic rxn rate 2% of inj; epi usage rate 0.38%, worst reaction was anaphylaxis (2) No systemic rxn in DM group, 15% of pts pollen group and 57% of pts in Alternaria group Perennial Ryegrass IT (8) Olive tree IT (3) Ryegrass + olive IT (35) A. Alternata IT (7)  Did not assess clinical efficacy  Maintenance dose unclear to me, unstandardized extracts

 Probable effective dose for cat immunotherapy: μg Fel d 1 StudySubjectsIT ScheduleAdverse rxns Ewbank, JACI cat allergic adults with AR ± intermittent asthma, pre-medicated with loratadine 10 mg PO 5 wks (6/5/4/3/1 inj per wk) to a maint dose of 0, 0.6, 3, or 15 μg Fel d 1 No systemic rxns 1 subject with repeated LLR Nanda, JAC I 04 As above + zafirlukast 20 mg PO 4 wks (8 visits) to a maint dose of 0, 0.6, 3, or 15 μg Fel d 1 1 subject with pruritus, treated with diphenhydramine

Clustered schedules in allergen SIT (Parmiani, Allergol et Imm 02)  Reviewed 21 studies involving aeroallergens from 80’s-90’s (rest were VIT)  Systemic rxn rates all <1% of inj in studies looking at cluster schedule “the following seem to be the best basic conditions to be further studied and properly combined for an optimal schedule” Use of a premedication to be administered between 15 and 60 minutes before the first administration of each cluster, especially in asthmatic patients. Use of depot preparations (Aluminum hydroxide adjuvant) Not more than 4 administrations per cluster. Between 4 and 6 clusters. Administration of one to two clusters per week.

1:10001:1001:10maintenance Systemic reaction shock +Angio edema Allergen dose over time Urticaria Lawsuit Premedication masking systemic reaction sx Mild or Subclinical

Antihistamine premedication in specific cluster IT: A DBPC study (Nielsen, JACI 1996) Subjects: Adult, AR to birch tree or timothy grass, premed taken 2h before inj IT ScheduleAdverse rxn rate Placebo (24) 7 wks (3/2/2/2/2/2/1 inj per wk) with birch OR timothy No serious systemic rxns/anaphylaxis in either group Early systemic rxn rate: loratadine 1.6% per inj, placebo 3.1% per inj Loratadine did not delay onset of systemic rxns, and significantly decreased severity of systemic rxns vs. placebo Loratadine 10 mg (21) AllergenMaint doseProbable eff. dose Phl p 525 μg μg Bet v 123 μg μg Systemic reactions not broken down by allergen used for immunotherapy

6 Systemic reactions 6 Systemic reactions 0 Systemic reactions 0 Systemic reactions Pretreat with placebo 26 Pretreat with placebo 26 Pretreat with terfenadine 26 Pretreat with terfenadine  Does premedication alter the efficacy of IT? 52 Bee allergic patients 52 Bee allergic patients Rush IT (4 inj/day x 4 days) Sting or field challenge (3 years later) Premedication with antihistamines may enhance efficacy of specific-allergen IT (Muller, JACI 2001)

 ACAAI instant reference:  “while there are no firm indications for accelerated schedules, the following patients and/or situations may benefit from such schedules” ▪ Poor adherence or systemic rxns with conventional IT ▪ Work/life schedule precludes weekly injections for a prolonged time ▪ Asthmatics that can only be controlled long enough to reach a maintenance dose with an accelerated schedule  David Khan, MD – Patient selection for rush and cluster IT (presented at AAAAI 2010)  “Summary: Any patient who is considered a candidate for IT is a candidate for cluster or RIT.”

Predicting Patients at High Risk of Systemic Reactions to Cluster IT: A Pilot Prospective Observational Study (Justicia, J Invest Clin Imm 06) Subjects: >12 yo, AR ± asthma IT SchedulesAdverse rxn rate Olive tree (253) 4 wk (3/3/2/2 or 2/2/2/2 inj per wk) 3 wk (2/2/2 or 2/2/2 inj per wk) 2 wk (3/2 inj per wk)  Systemic rxn rate 1.8% of inj, no life-threatening rxns.  Significant risk factors for systemic rxn: age > 14 +SPT to goosefoot olive/grass sIgE:total IgE ratio > 20% olive only IT faster schedules Olive tree + “the most important grasses from our region” mix (358)  Maintenance dose or identity/number of grass allergens not reported  Cluster schedule very aggressive compared to AIPP

Safety and Immunogenicity of Cluster IT in Children with Asthma and Mite Allergy (Schubert, Int Arch All Imm 2009)

DB comparative study of cluster and conventional IT schedules with D. pteronyssinus (Tabar, JACI 05) Cutaneous Tolerance Index (CTI) = number of times in which it is necessary to multiply the concentrations of an extract, in order to obtain the same wheal areas as those obtained by the same concentrations of another extract

 Cluster immunotherapy is as safe and cheaper/faster than conventional IT.  Premedication further diminishes the risk of a serious systemic reaction.  AIPP example cluster schedule is more conservative than many of the studies reviewed today, and in some cases our maintenance dose would be lower.  Let’s do premedicated cluster IT here! Get your shots and gooooooo!